Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.Peer-Reviewed Original ResearchIGFBP-7 levelsAdjusted hazard ratioReduced ejection fractionEffect of dapagliflozinIGFBP-7NT-proBNPPrimary outcomeEjection fractionHeart failureDAPA-HFNYHA classCause mortalityHF eventsHighest thirdCorresponding adjusted hazard ratioMore type 2 diabetesHigh-sensitivity troponin TInsulin-like growth factor binding protein 7Growth factor binding protein 7Adverse HF outcomesBenefit of dapagliflozinDAPA-HF trialEfficacy of dapagliflozinHigher NYHA classNYHA class II